Meet Mindset Pharma, a Leader in the Race to Develop Next-Gen Psychedelic Compounds

Similar Posts

Removing Barriers of Accessibility to Psychedelics with Brett Waters

Removing Barriers of Accessibility to Psychedelics with Brett Waters

Listen, Podcasts

Brett also introduces the collaborative efforts of Reason for Hope’s team, which includes strategic minds from various fields, working together in drafting legislation, preparing legal briefings, educating legislators, and building advocacy coalitions. Currently, Reason for Hope focuses on establishing MDMA- and psilocybin-assisted therapy expanded access pilot programs for those unable to wait for FDA approval.

50 of the Greatest Psychedelic Quotes of All Time

50 of the Greatest Psychedelic Quotes of All Time

Culture, Listen

“Psychedelics and plant-based medicines are powerful tools in the process of healing, particularly for the most marginalized folks living under empire, who are underserved, underrepresented and experience the highest rates of violence. Marginalized communities already have limited access to healing spaces, so I think t’s important for folks invested in justice work to center and prioritize what nontraditional forms of healing look like for these communities.”

MindMed’s CEO RESIGNS! What’s NEXT for MMED / MNMD Stock? [ My Thoughts? ]

MindMed’s CEO RESIGNS! What’s NEXT for MMED / MNMD Stock? [ My Thoughts? ]

Listen, Videos

MindMed Changes CEO? Hey Guys! What a day it has been! Today, MindMed (MMED :NEO),
(MNMD: NASDAQ), and (MMQ: FRA) has announced that JR Rahn has stepped down as CEO of MindMed effective immediately. Chief Development Officer, Robert Barrow will assume the role while MindMed is considering possible candidates.

In this episode, we’ll cover several things.

1.What happened?
2.My general thoughts on the leadership change.
3.My thoughts on JR Rahn’s successes and his departure.
4.What Robert Barrow brings to the table as CEO.

Links:
MindMed changes leadership:
https://mindmed.co/news/press-release/mindmed-announces-chief-executive-officer-transition/

Robert Barrow background:
https://mindmed.co/team/robert-barrow-1/
https://www.newswire.ca/news-releases/mindmed-adds-chief-development-officer-with-fda-phase-2-psilocybin-clinical-trial-experience-862550304.html

General Reddit sentiment about MindMed’s leadership change:
https://www.reddit.com/r/MindMedInvestorsClub/comments/nvwtou/expected_this_sub_to_be_on_fire_this_morning_but/

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MNMD #MindmedNews